Breaking News Instant updates and real-time market news.

AMGN

Amgen

$207.54

5.22 (2.58%)

16:02
11/30/18
11/30
16:02
11/30/18
16:02

Amgen, UCB say FDA to review EVENITY

Amgen and UCB announced the U.S. Food and Drug Administration Bone, Reproductive and Urologic Drugs Advisory Committee, or BRUDAC, will review data supporting the Biologics License Application for EVENITY for the treatment of osteoporosis in postmenopausal women at high risk for fracture at a meeting on Jan. 16, 2019. "After a fracture, postmenopausal women with osteoporosis are five times more likely to fracture in the subsequent year, and these fractures can be life-changing. Yet these patients often remain undiagnosed and untreated and could benefit from a potential new bone forming therapy that has been shown to reduce their risk of fracture within the first year," said David M. Reese, M.D., executive vice president of Research and Development at Amgen. "We look forward to discussing the efficacy and safety data from our EVENITY clinical program with the members of the Committee." "We are currently seeing a large gap in the management and treatment of osteoporosis, especially in the post-fracture setting, with an estimated 77 percent of women aged 67 or older remaining undiagnosed and untreated in the first six months after a fracture.4 This is a stark reminder of the need to improve post-fracture care and reduce the risk of future fractures," said Dr. Pascale Richetta, head of bone and executive vice president, UCB. "We believe EVENITY has the potential to help postmenopausal women with osteoporosis who are at high risk for fracture, and we look forward to the interactions with the members of the Committee."

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

AMGN Amgen
$207.54

5.22 (2.58%)

11/19/18
CANT
11/19/18
NO CHANGE
Target $68
CANT
Overweight
Tesaro could be worth $89-$97 per share in buyout, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young believes Tesaro (TSRO) could be valued at $89-$97 per share in a takeout scenario. The stock closed Friday up 31%, or $8.37, to $34.96 after Bloomberg reported that the company was exploring a sale after receiving some interest. The press article could be a way of garnering interest for the company beyond potentially initial interest, Young tells investors in a research note. In the past, she thinks Tesaro has been a potential takeout interest from biopharmaceutical companies. Companies like Amgen (AMGN), Gilead (GILD), and Celgene (CELG) have cancer platforms that could add a PARP inhibitor and benefit from Tesaro's various immuno-oncology pipeline assets, Young writes. She reiterates an Overweight rating on Tesaro with a $68 price target.
10/31/18
RBCM
10/31/18
NO CHANGE
Target $182
RBCM
Sector Perform
Amgen price target lowered to $182 from $193 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Amgen to $182 and kept his Sector Perform rating after its Q3 results. The analyst says the quarter was "in line" with "safe" expectations, even as the company's core business competition is "slow" to impact sales. MacKay further cites an "astonishing" launch of Aimovig with 100K new patients, but also notes the sales decline against sequential volume growth for Amgen's Repatha.
10/29/18
PIPR
10/29/18
NO CHANGE
PIPR
Neutral
Piper sees Amgen's Aimovig pressuring Allergan's Botox in near term
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Amgen (AMGN) and Neutral rating on Allergan (AGN) after his firm's Overweight based on feedback from a migraine survey fielded by his firm's partner Spherix Global Insights. The analyst is "struck by the progress" Amgen has made just months into Aimovig's launch, specifically on sales coverage, message delivery and overall credibility with physicians. It appears that Allergan's Botox "could be in for some pressure in the near term at the direct hands" of Amgen's Aimovig, Raymond tells investors in a research note titled "Aiming for Aimovig; New Migraine Survey Indicates Aimovig the Star of the Show." Doctors are projecting peak Aimovig share of 49% and 29% for chronic and episodic patients respectively, which infers peak U.S. revenue for the drug at $3.3B, the analyst says. Further, he notes that of the 98 high volume migraine specialists surveyed, 43% versus 29% agreed with the statement: "I am more likely to prescribe Aimovig over Botox due to access to patient assistance program."
10/25/18
MSCO
10/25/18
NO CHANGE
Target $212
MSCO
Overweight
Repatha list price cut has benefits for Amgen, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Amgen announced that it is reducing Repatha's list price by 60%, stating that he believes the new list price of $5,850/year is similar to the current net price for the treatment. He also noted that Amgen management said they anticipate little impact to long-term blended net price, though there could be some volatility in the near-term. Given the current political environment, he sees two key benefits to the strategy, namely that it is "a novel SKU strategy" and second the lower price likely improves a structural headwind since Repatha is largely a Medicare product. Harrison keeps an Overweight rating on Amgen shares.

TODAY'S FREE FLY STORIES

BCRX

BioCryst

$2.03

0.33 (19.41%)

16:52
11/19/19
11/19
16:52
11/19/19
16:52
Hot Stocks
Breaking Hot Stocks news story on BioCryst »

BioCryst up over 10% at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

BCRX

BioCryst

$2.03

0.33 (19.41%)

16:51
11/19/19
11/19
16:51
11/19/19
16:51
Hot Stocks
Point72 reports 6.1% passive stake in BioCryst »

Point72 disclosed a 6.1%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

QTT

Qutoutiao

$2.99

-0.1 (-3.24%)

16:50
11/19/19
11/19
16:50
11/19/19
16:50
Syndicate
Qutoutiao files to sell 1.48M Class A ordinary shares for holders »

Represented by up to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTT

Qutoutiao

$2.99

-0.1 (-3.24%)

16:49
11/19/19
11/19
16:49
11/19/19
16:49
Syndicate
Qutoutiao files to sell $80M of Class A ordinary shares »

Including Class A…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNVR

Univar

$22.85

-0.3 (-1.30%)

, BA

Boeing

$366.93

-2.57 (-0.70%)

16:48
11/19/19
11/19
16:48
11/19/19
16:48
Hot Stocks
Univar signs 10-year contract extension with Boeing South Carolina »

Univar Solutions (UNVR)…

UNVR

Univar

$22.85

-0.3 (-1.30%)

BA

Boeing

$366.93

-2.57 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STIM

Neuronetics

$4.13

(0.00%)

16:44
11/19/19
11/19
16:44
11/19/19
16:44
Hot Stocks
Neuronetics CFO Furlong buys 23K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VERO

Venus Concept

$3.29

-0.07 (-2.08%)

16:43
11/19/19
11/19
16:43
11/19/19
16:43
Hot Stocks
Venus Concept receives Health Canada OK to market Venus Bliss in Canada »

Venus Concept announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEM

Agnico Eagle

$60.20

0.88 (1.48%)

16:43
11/19/19
11/19
16:43
11/19/19
16:43
Syndicate
Breaking Syndicate news story on Agnico Eagle »

Agnico Eagle files $1B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$22.73

0.1 (0.44%)

16:43
11/19/19
11/19
16:43
11/19/19
16:43
Hot Stocks
Breaking Hot Stocks news story on Amarin »

Amarin drops 3% to $21.98…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

SUMR

Summer Infant

$0.31

-0.0041 (-1.30%)

16:43
11/19/19
11/19
16:43
11/19/19
16:43
Hot Stocks
SUMR Brands announces CEO Mark Messner to step down »

SUMR Brands announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$6.85

-0.22 (-3.11%)

16:42
11/19/19
11/19
16:42
11/19/19
16:42
Periodicals
Fire victims claim $11B insurance agreement is blocking PG&E deal, WSJ says »

Victims of wildfires…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

ALC

Alcon

$59.00

0.105 (0.18%)

16:42
11/19/19
11/19
16:42
11/19/19
16:42
Hot Stocks
Alcon announces transformation program, expects $300M in costs »

Following a comprehensive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 02

    Dec

BDSI

BioDelivery Sciences

$6.14

0.06 (0.99%)

16:41
11/19/19
11/19
16:41
11/19/19
16:41
Hot Stocks
BioDelivery Sciences director sells 200K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

USO

United States Oil Fund

$11.57

-0.33 (-2.77%)

16:40
11/19/19
11/19
16:40
11/19/19
16:40
General News
API crude inventories for week of November 15 »

API reports that crude…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URBN

Urban Outfitters

$28.73

-1.43 (-4.74%)

, ANF

Abercrombie & Fitch

$16.79

-0.295 (-1.73%)

16:39
11/19/19
11/19
16:39
11/19/19
16:39
Hot Stocks
Urban Outfitters drops 12% after Q3 results, teen retail peers follow lower »

Shares of Urban…

URBN

Urban Outfitters

$28.73

-1.43 (-4.74%)

ANF

Abercrombie & Fitch

$16.79

-0.295 (-1.73%)

AEO

American Eagle

$15.24

-0.5 (-3.18%)

GPS

Gap

$16.77

-0.525 (-3.04%)

ZUMZ

Zumiez

$29.80

-0.08 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 21

    Nov

  • 26

    Nov

  • 05

    Dec

  • 11

    Dec

ALC

Alcon

$59.00

0.105 (0.18%)

16:38
11/19/19
11/19
16:38
11/19/19
16:38
Earnings
Breaking Earnings news story on Alcon »

Alcon tightens FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 02

    Dec

FIX

Comfort Systems USA

$50.48

-0.07 (-0.14%)

16:38
11/19/19
11/19
16:38
11/19/19
16:38
Hot Stocks
Comfort Systems USA authorizes additional buyback of 764.8K shares of stock »

Comfort Systems USA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

ALC

Alcon

$59.00

0.105 (0.18%)

16:36
11/19/19
11/19
16:36
11/19/19
16:36
Earnings
Alcon reports Q3 core EPS 46c, consensus 46c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 02

    Dec

BBT

BB&T

$54.71

-0.3 (-0.55%)

, STI

SunTrust

$70.73

-0.27 (-0.38%)

16:36
11/19/19
11/19
16:36
11/19/19
16:36
Hot Stocks
BB&T, SunTrust receive regulatory approvals for merger of equals »

BB&T Corporation…

BBT

BB&T

$54.71

-0.3 (-0.55%)

STI

SunTrust

$70.73

-0.27 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LDOS

Leidos

$91.73

0.35 (0.38%)

16:33
11/19/19
11/19
16:33
11/19/19
16:33
Hot Stocks
Leidos names Sanjay Parthasarathy as business development and strategy VP »

Leidos announced that Dr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NXPI

NXP Semiconductors

$113.92

-2.02 (-1.74%)

16:33
11/19/19
11/19
16:33
11/19/19
16:33
Hot Stocks
NXP Semiconductors to resume share buy-back program in 2020 »

NXP board of directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

NXPI

NXP Semiconductors

$113.92

-2.02 (-1.74%)

16:32
11/19/19
11/19
16:32
11/19/19
16:32
Hot Stocks
NXP Semiconductors announces 37.5c interim dividend for Q4 »

NXP Semiconductors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

MGP

MGM Growth

$32.46

-0.39 (-1.19%)

16:30
11/19/19
11/19
16:30
11/19/19
16:30
Syndicate
MGM Growth 24M share Spot Secondary; price range $31.25-$31.75 »

JPMorgan, Morgan Stanley,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
11/19/19
11/19
16:30
11/19/19
16:30
Options
Preliminary option volume of 19.3M today »

Preliminary option volume…

VAL

Valaris

$3.69

-0.51 (-12.14%)

16:29
11/19/19
11/19
16:29
11/19/19
16:29
Initiation
Valaris initiated  »

Valaris initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.